[{"address1": "9350 Kirby Drive", "address2": "Suite 300", "city": "Houston", "state": "TX", "zip": "77054", "country": "United States", "phone": "713 400 6400", "website": "https://www.markertherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.", "companyOfficers": [{"maxAge": 1, "name": "Ms. Elizabeth  Donnelly", "title": "Director of Administration", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Cheung", "title": "Vice President of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nadia  Agopyan Ph.D.", "title": "Senior Vice President of Regulatory Affairs", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Monic  Stuart M.D.", "title": "Chief Medical Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gerald  Garrett", "title": "Senior Vice President of Clinical Operations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Z. Florkiewicz Sr.", "title": "Senior Director of Molecular Biology & Virology", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 4.71, "open": 4.785, "dayLow": 4.57, "dayHigh": 4.785, "regularMarketPreviousClose": 4.71, "regularMarketOpen": 4.785, "regularMarketDayLow": 4.57, "regularMarketDayHigh": 4.785, "beta": 1.485, "forwardPE": -1.3823528, "volume": 6344, "regularMarketVolume": 6344, "averageVolume": 20195, "averageVolume10days": 27140, "averageDailyVolume10Day": 27140, "bid": 3.4, "ask": 5.93, "bidSize": 200, "askSize": 200, "marketCap": 41778392, "fiftyTwoWeekLow": 0.76, "fiftyTwoWeekHigh": 9.68, "priceToSalesTrailing12Months": 12.617552, "fiftyDayAverage": 4.2842, "twoHundredDayAverage": 4.4317, "currency": "USD", "enterpriseValue": 23470050, "profitMargins": -2.48761, "floatShares": 6741394, "sharesOutstanding": 8889020, "sharesShort": 149703, "sharesShortPriorMonth": 177922, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.0168, "heldPercentInsiders": 0.12167, "heldPercentInstitutions": 0.22950001, "shortRatio": 8.33, "shortPercentOfFloat": 0.0234, "impliedSharesOutstanding": 9936000, "bookValue": 1.579, "priceToBook": 2.9765673, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -14045895, "trailingEps": -2.86, "forwardEps": -3.4, "lastSplitFactor": "1:10", "lastSplitDate": 1674777600, "enterpriseToRevenue": 7.088, "enterpriseToEbitda": -1.99, "52WeekChange": 4.6626506, "SandP52WeekChange": 0.27320957, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MRKR", "underlyingSymbol": "MRKR", "shortName": "Marker Therapeutics, Inc.", "longName": "Marker Therapeutics, Inc.", "firstTradeDateEpochUtc": 1026826200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f52316f7-d523-378a-bebe-a89c89d1c289", "messageBoardId": "finmb_1725474", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.7, "targetHighPrice": 12.5, "targetLowPrice": 12.5, "targetMeanPrice": 12.5, "targetMedianPrice": 12.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 15111450, "totalCashPerShare": 1.698, "ebitda": -11792272, "quickRatio": 5.249, "currentRatio": 5.57, "totalRevenue": 3311133, "revenuePerShare": 0.376, "returnOnAssets": -0.35358003, "returnOnEquity": -0.83472997, "freeCashflow": -9563713, "operatingCashflow": -16439961, "revenueGrowth": -0.681, "grossMargins": -2.14599, "operatingMargins": -2.7806, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-10"}]